Overview

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

Status:
Active, not recruiting

Trial end date:
2024-05-21

Target enrollment:

Participant gender:

Summary

This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Avelumab
Axitinib
Sunitinib